Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

Executive Summary

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

You may also be interested in...



FDA's Opioid Programs: After Training, What's The Next Step?

Treatment guidelines may also appear in opioid labeling, and insurers seem to be taking the agency's advice, but will it be enough to satisfy Congress?

Abuse-Deterrent Opioid Manufacturers Want FDA To Set Conversion Deadline

US agency denied group's 2013 citizen petition, but with more abuse-deterrent products on the market, sponsors hope climate is more favorable for idea that older opioids should come off market once three similar abuse-deterrent products are available.

Abuse-Deterrent Opioid Manufacturers Want FDA To Set Conversion Deadline

US agency denied group's 2013 citizen petition, but with more abuse-deterrent products on the market, sponsors hope climate is more favorable for idea that older opioids should come off market once three similar abuse-deterrent products are available.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel